FDA OK for Cepheid's Xpert MRSA tests
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for two of Cepheid’s diagnostics for the detection of Staphylococcus aureus (SA) and methicillin-resistant S aureus (MRSA). The first was for its Xpert MRSA/SA SSTI (skin and soft tissue infections) test, which detects the bacteria in suspicious wounds or skin infections. The second is the Xpert MRSA/SA BC (blood culture) test, which detects the bacteria in Gram-positive blood culture bottles in patients with signs of life-threatening bloodstream infections. Both diagnostics produce results in under an hour, run on the GeneXpert System, and cost $75. Existing blood culture tests take up to 48 hours and patients receive broad-spectrum antibiotics in the interim which could lead to resistance, Sunnyvale, California-based Cepheid says.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.